评价16α-18F-氟-17β-氟雌二醇（18F-FES）PET/CT对雌激素受体（ER）阳性乳腺癌患者远处转移或复发的诊断价值。ER阳性乳腺癌且疑似患者从我们机构登记参加 18F-FES 上市后监测研究的前瞻性队列中回顾性地确定了新发转移或复发的情况。使用病理学或 2 种或更多标准护理成像程序评估每位患者的诊断准确性，并以至少 6 个月的随访作为参考标准。对 18F-FES PET/CT 的每区域检出率进行了评估，并与标准护理成像进行比较。在纳入的 162 名患者中，分别有 104 名和 58 名疑似复发或新发转移。 18F-FES PET/CT 的总体敏感性和特异性分别为 95%（95% 置信区间 [CI]，89%-98%）和 89%（95% CI，76%-96%）。根据临床情况分层时，检测复发的敏感性和特异性分别为 95%（95% CI，88%-99%）和 96%（95% CI，78%-100%），94%（95% CI，78%-100%）。 95% CI, 81%-99%) 和 82% (95% CI, 60%-95%) 用于检测远处转移。在基于区域的分析中，18F-FES PET/CT 的总体检出率显着高于标准护理成像（92% [95% CI, 89%-94%] vs 83% [95% CI , 79%-87%], P < 0.001).18F-FES PET/CT 在疑似新发转移或复发的 ER 阳性乳腺癌患者中显示出出色的诊断性能。版权所有 © 2024 Wolters Kluwer Health, Inc. 所有权利预订的。

To evaluate the diagnostic value of 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) PET/CT for distant metastasis or recurrence in patients with estrogen receptor (ER)-positive breast cancer.Patients with ER-positive breast cancer and suspected of de novo metastasis or recurrence were retrospectively identified from a prospective cohort enrolled for a postmarketing surveillance study of 18F-FES at our institution. Per-patient diagnostic accuracy was assessed using pathology or 2 or more standard-of-care imaging procedures with a minimum of 6 months of follow-up as the reference standard. The per-region detection rate of 18F-FES PET/CT was evaluated and compared with that of standard-of-care imaging.Of the 162 included patients, 104 and 58 were suspected to have recurrence or de novo metastasis, respectively. The overall sensitivity and specificity of 18F-FES PET/CT were 95% (95% confidence interval [CI], 89%-98%) and 89% (95% CI, 76%-96%), respectively. When stratified according to clinical settings, the sensitivity and specificity were 95% (95% CI, 88%-99%) and 96% (95% CI, 78%-100%), respectively, for detecting recurrence, and 94% (95% CI, 81%-99%) and 82% (95% CI, 60%-95%) for detecting distant metastasis. In region-based analysis, the overall detection rate of 18F-FES PET/CT was significantly higher than that of standard-of-care imaging (92% [95% CI, 89%-94%] vs 83% [95% CI, 79%-87%], P < 0.001).18F-FES PET/CT showed excellent diagnostic performance in patients with ER-positive breast cancer suspected of de novo metastasis or recurrence.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.